Sarah Sheikh

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

Ralf Gold, Ludwig Kappos, Douglas L. Arnold et al. · New England Journal of Medicine · 2012 · 1.7K citations · Full text

Medicine, Neurology, Pharmacotherapy +17

Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial

Diego Cadavid, Michelle Mellion, Raymond Hupperts et al. · The Lancet Neurology · 2019 · 185 citations

Life Sciences, Immunology, Neurology +11

Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE

Bernd C. Kieseier, Douglas L. Arnold, Laura J. Balcer et al. · Multiple Sclerosis Journal · 2014 · 113 citations · Full text

Pharmacy, Neurology, Pharmacotherapy +12

Risk of Confirmed Guillain-Barre Syndrome Following Receipt of Monovalent Inactivated Influenza A (H1N1) and Seasonal Influenza Vaccines in the Vaccine Safety Datalink Project, 2009-2010

Sharon K. Greene, Melisa D. Rett, Eric Weintraub et al. · American Journal of Epidemiology · 2012 · 90 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1

Yves Dauvilliers, Emmanuel Mignot, Rafael del Río Villegas et al. · New England Journal of Medicine · 2023 · 86 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17